In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases.
about
P2X receptors as targets for the treatment of status epilepticusRole of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: Control of amyloid plaques formation "in vivo" by P2X7 receptorThe two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brainNeuronal and glial purinergic receptors functions in neuron development and brain diseaseNLRP3 Inflammasome in Neurological Diseases, from Functions to TherapiesOral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model.Effect of genetic deletion and pharmacological antagonism of P2X7 receptors in a mouse animal model of migraine.Inflammasomes as therapeutic targets for Alzheimer's disease.The role of nucleotides and purinergic signaling in apoptotic cell clearance - implications for chronic inflammatory diseases.ATP as a multi-target danger signal in the brain.The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system.miR-186 is decreased in aged brain and suppresses BACE1 expressionPurinergic receptors as potential therapeutic targets in Alzheimer's disease.D-serine in the midbrain periaqueductal gray contributes to morphine tolerance in rats.Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control.Neurotransmitter signaling in the pathophysiology of microglia.Central nervous system myeloid cells as drug targets: current status and translational challenges.Silencing of P2X7R by RNA interference in the hippocampus can attenuate morphological and behavioral impact of pilocarpine-induced epilepsy.P2X7 receptor-pannexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells.Presenilin 2 deficiency facilitates Aβ-induced neuroinflammation and injury by upregulating P2X7 expression.PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions.Roles of extracellular nucleotides and P2 receptors in ectodomain shedding.The microglial ATP-gated ion channel P2X7 as a CNS drug target.Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release.Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.Evaluation of the Anticonvulsant Effect of Brilliant Blue G, a Selective P2X7 Receptor Antagonist, in the iv PTZ-, Maximal Electroshock-, and 6 Hz-Induced Seizure Tests in MiceIncreased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079.When too much ATP is a bad thing: a pivotal role for P2X7 receptors in motor neuron degeneration.An Update on P2Y13 Receptor Signalling and Function.The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?Diverse effects of Brilliant Blue G administration in models of trigeminal activation in the rat.ATP-P2X7 Receptor Modulates Axon Initial Segment Composition and Function in Physiological Conditions and Brain Injury.Cobalt Protoporphyrin Upregulates Cyclooxygenase-2 Expression Through a Heme Oxygenase-Independent Mechanism.Coordinate effects of P2X7 and extracellular acidification in microglial cells.Coordinate effects of P2X7 and extracellular acidification in microglial cells.Fast Green FCF Alleviates Pain Hypersensitivity and Down-Regulates the Levels of Spinal P2X4 Expression and Pro-inflammatory Cytokines in a Rodent Inflammatory Pain Model.The Neurotoxic Role of Extracellular Tau Protein.Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse modelThe Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases
P2860
Q26823175-859AB9CD-66B6-425F-9F21-7C75BE2911A8Q26824248-10ECEA9B-6337-4680-97C1-70D6F705BFDAQ26824833-8AFAF1B1-5D45-40DF-AC40-704C6E5703DAQ27500377-90EDB714-E0A5-4DE8-85A1-BB9948A2979EQ29248417-1C13A534-2DF2-4463-BE2F-29E4CB99A50FQ30277388-4C1DC4D6-2A09-44E1-B751-FE11C7DA80FBQ33593128-676D2406-F3D7-434A-AFDD-4088CE1BB2A9Q34547897-253665E7-E037-4C86-B23F-CD84BCA869EFQ34763427-B05A13F3-A967-40DB-B997-E51844D72D09Q35545478-D1E1000C-5B0C-402C-A80E-57A7D256D6E6Q36492899-EA298B62-B601-4631-B97B-E86FD097C0D8Q36813933-3C671E4B-66AE-4FF0-8011-A93C395B4431Q36844881-3FE66475-DAA4-438D-974F-21B7D2B76A94Q37114777-53BEADCF-0775-4508-B3FD-D21CD65E2A90Q37219098-7469B176-601C-4E26-ACCA-093CD9184D2DQ38074161-13305A63-5EE5-42A7-90CC-FC884149F85DQ38102686-35B7661F-9A2B-4F96-91F2-9146E850425CQ38658658-6597B664-D3C1-48E6-B5E3-ED6ED68E8410Q38679789-9E20EA91-D615-4ACE-AE84-F73B77F39E69Q38703135-2EBA7780-CBE8-4105-A269-8C15526FB29EQ38719556-9A5D1A88-B6A7-4E4F-9D9E-2E5540AEBB51Q38810232-2244CFE2-D4AC-4740-AC1B-C9BC58B213EEQ38834775-065D733A-1EF3-49D5-BB55-B8C5AE507461Q38843107-06C471CC-9F82-4A4D-A1F7-CF24C2AB18E2Q39771468-A5C24CB7-51E1-405B-ACF8-712C245783ACQ42005467-6D648C66-C7E2-4EF4-8D8D-7F674911CEE8Q42727469-4AA51100-754D-4B2D-ADAA-294363EEEC35Q43963291-43A11111-0628-4785-B74C-CBAABCEC949EQ46313886-2F2FC8BB-DAA0-403E-ACE9-FE901A5678B9Q47943130-FBF812C1-2D1F-4447-829F-A771F5D53FCFQ50202418-088365D6-72B7-49FA-8E7D-78AF84283F71Q50210809-1CB7BA9D-3C35-4437-A930-0D73AF3A461EQ50224719-4ED2C7CC-F3DF-48F1-A7CC-FC94BB8B678AQ51816792-C1A9D363-6D84-4B18-AFB7-2BFB0438C8D1Q52645864-858B2064-9D99-43A7-96BC-E931AF473F1DQ54954928-5F39937D-2326-4738-94AD-95D7E45DC563Q55027191-4742F77D-FB81-45EA-94A1-CB950CA35414Q55080849-C434977E-5A91-4D13-A5CF-35EA570F3770Q58698909-08F82E21-73C5-4EED-8194-6D3514C6D314Q58787876-101D3C7B-576F-4C8A-87B2-ADCF9EC6FD53
P2860
In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
In vivo P2X7 inhibition reduce ...... through GSK3β and secretases.
@en
In vivo P2X7 inhibition reduce ...... through GSK3β and secretases.
@nl
type
label
In vivo P2X7 inhibition reduce ...... through GSK3β and secretases.
@en
In vivo P2X7 inhibition reduce ...... through GSK3β and secretases.
@nl
prefLabel
In vivo P2X7 inhibition reduce ...... through GSK3β and secretases.
@en
In vivo P2X7 inhibition reduce ...... through GSK3β and secretases.
@nl
P2093
P50
P1476
In vivo P2X7 inhibition reduce ...... e through GSK3β and secretases
@en
P2093
Ana Del Puerto
Javier Gualix
Jose Luis Trejo
Juan Ignacio Diaz-Hernandez
Lourdes Hontecillas-Prieto
Miguel Diaz-Hernandez
Miriam León-Otegui
P304
P356
10.1016/J.NEUROBIOLAGING.2011.09.040
P577
2011-11-01T00:00:00Z